NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant The USPTO issued a patent to NAPIGEN for the use of CRISPR technologies to edit organellar genomes. Separately, USDA awarded NAPIGEN an SBIR phase 1 grant.

NAPIGEN Completes $7.85 Million Funding Round to Advance Its Mitochondrial and Chloroplast Gene Editing Technology WILMINGTON, Del., July 12, 2022 (GLOBE NEWSWIRE) -- NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round. ...

NAPIGEN Publication Provides Proof of Concept of its Technology for Editing Cytoplasmic Genome (Mitochondrial and Chloroplast Genome) WILMINGTON, Del., Jan. 28, 2020 (GLOBE NEWSWIRE) -- NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, said it demonstrated for the first time the...